Progyny, Inc. (NASDAQ:PGNY) Shares Purchased by Pacer Advisors Inc.

Pacer Advisors Inc. boosted its holdings in shares of Progyny, Inc. (NASDAQ:PGNY) by 12,579.4% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,492,642 shares of the company’s stock after acquiring an additional 2,472,983 shares during the quarter. Pacer Advisors Inc. owned about 2.76% of Progyny worth $41,777,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of the business. RiverPark Advisors LLC raised its holdings in Progyny by 9.6% in the 2nd quarter. RiverPark Advisors LLC now owns 5,408 shares of the company’s stock valued at $155,000 after buying an additional 474 shares during the period. Arizona State Retirement System lifted its holdings in shares of Progyny by 2.6% in the 2nd quarter. Arizona State Retirement System now owns 24,313 shares of the company’s stock worth $696,000 after acquiring an additional 609 shares during the last quarter. State of New Jersey Common Pension Fund D boosted its position in shares of Progyny by 1.1% during the 2nd quarter. State of New Jersey Common Pension Fund D now owns 70,717 shares of the company’s stock worth $2,023,000 after purchasing an additional 787 shares during the period. Quarry LP raised its position in Progyny by 1,900.0% in the second quarter. Quarry LP now owns 880 shares of the company’s stock valued at $25,000 after purchasing an additional 836 shares during the period. Finally, Creative Planning lifted its stake in Progyny by 13.8% during the second quarter. Creative Planning now owns 10,564 shares of the company’s stock worth $302,000 after purchasing an additional 1,283 shares in the last quarter. Institutional investors and hedge funds own 94.93% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on PGNY shares. Jefferies Financial Group cut their price objective on Progyny from $31.00 to $24.00 and set a “buy” rating on the stock in a report on Thursday, September 19th. Cantor Fitzgerald reissued an “overweight” rating and issued a $25.00 price objective on shares of Progyny in a research note on Tuesday, October 1st. BTIG Research lowered shares of Progyny from a “buy” rating to a “neutral” rating in a report on Wednesday, August 7th. JMP Securities cut shares of Progyny from an “outperform” rating to a “market perform” rating in a research report on Thursday, September 19th. Finally, Bank of America cut their price objective on Progyny from $22.00 to $21.00 and set a “buy” rating on the stock in a research report on Wednesday, November 13th. Eight equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $25.42.

Progyny Stock Up 7.1 %

Shares of PGNY opened at $14.97 on Friday. The company has a market capitalization of $1.27 billion, a price-to-earnings ratio of 25.81, a price-to-earnings-growth ratio of 1.65 and a beta of 1.44. Progyny, Inc. has a 52-week low of $13.39 and a 52-week high of $42.08. The stock has a 50 day moving average price of $16.58 and a 200 day moving average price of $22.86.

Progyny (NASDAQ:PGNY) last issued its quarterly earnings data on Tuesday, November 12th. The company reported $0.11 earnings per share for the quarter, missing the consensus estimate of $0.37 by ($0.26). The company had revenue of $286.63 million for the quarter, compared to analysts’ expectations of $296.85 million. Progyny had a return on equity of 11.36% and a net margin of 5.03%. The firm’s quarterly revenue was up 2.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.16 EPS. On average, equities analysts anticipate that Progyny, Inc. will post 0.56 EPS for the current fiscal year.

Progyny Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.